サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1579689

創薬サービスの世界市場

Drug Discovery Services

出版日
ページ情報
英文 89 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
創薬サービスの世界市場
出版日: 2024年10月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 89 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

創薬サービスの世界市場は2030年までに611億米ドルに達する見込み

2023年に486億米ドルと推定された創薬サービスの世界市場は、分析期間2023-2030年にCAGR 3.3%で成長し、2030年には611億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである医薬化学サービスは、CAGR 4.0%を記録し、分析期間終了時には316億米ドルに達すると予測されます。生物学サービス分野の成長率は、分析期間中CAGR 2.8%と推定されます。

米国市場は129億米ドルと推定、中国はCAGR6.9%で成長予測

米国の創薬サービス市場は2023年に129億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに141億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは6.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.8%と1.5%と予測されています。欧州では、ドイツがCAGR 1.4%で成長すると予測されています。

世界の創薬サービス市場- 主要動向と促進要因のまとめ

創薬サービスは医薬品研究開発をどのように加速させているか？

創薬サービスは、医薬品開発の重要な段階を専門サービスプロバイダーにアウトソーシングすることを可能にし、スピード、効率性、費用対効果を高めることで、医薬品の研究開発（R&D）を変革しています。これらのサービスプロバイダー（多くの場合、開発業務受託機関（CRO））は、ハイスループットスクリーニング、リード化合物同定、前臨床研究、臨床試験などの分野で専門知識を提供し、製薬企業が外部の能力を活用しながら自社のコアコンピタンスに集中できるようにしています。初期段階の研究開発をアウトソーシングすることで、企業は有望な新薬候補を迅速に特定し、臨床試験に進めることができます。

医薬品開発プロセスの迅速化に加え、創薬サービスは、製薬会社が高コスト、規制上の課題、高度な技術要件など、現代の研究開発の複雑さを乗り切るのを支援します。CROは、次世代シーケンシング、プロテオミクス、バイオインフォマティクスなどの最先端技術へのアクセスを提供し、データ集約型の研究や的を絞った医薬品開発をサポートします。このパートナーシップ・モデルは、大規模な社内研究開発部門を維持するリソースがないにもかかわらず、イノベーションを推進し、市場で競争しようとする中小規模のバイオテクノロジー企業にとって特に価値があります。

創薬サービスにおいてテクノロジーが果たす役割とは？

テクノロジーは、人工知能（AI）、機械学習、バイオインフォマティクス、ハイスループットスクリーニングの進歩により、創薬サービスの能力と効率を高める上で極めて重要な役割を果たしています。AIと機械学習アルゴリズムにより、CROは大規模なデータセットを解析して潜在的な医薬品候補を特定し、化合物の相互作用を予測し、標的特異性と有効性に基づいてリード化合物を最適化することができます。ハイスループットスクリーニング技術により、生物学的標的に対する数千の化合物の迅速な試験が可能になり、創薬プロセスの初期段階で有望な候補化合物を特定し、研究開発段階での進行を加速することができます。

さらに、計算モデリングとシミュレーション技術は、臨床試験に入る前に薬剤候補の薬物動態特性や潜在的な毒性を予測するのに役立ち、コストのかかる後期段階での失敗を減らすことができます。バイオインフォマティクスと分子生物学ツールは、遺伝子やタンパク質のデータ解析を可能にし、より正確な薬剤ターゲティングを可能にします。このような技術革新により、創薬サービス・プロバイダーは高度な調査能力を備え、より安全で効果的な医薬品をより早く、より効率的に市場に送り出すという製薬会社の使命をサポートしています。

製薬会社が創薬サービスを利用するようになった理由

製薬会社は、研究開発の効率を最適化し、専門的な知識を利用し、自社開発にかかるコストを削減するために、創薬サービスへの依存度を高めています。研究開発インフラを維持するためには、専門の研究者の雇用や研究機器への投資など、高い固定費がかかるため、アウトソーシングが現実的な選択肢となっています。創薬サービスを通じて、製薬会社はターゲット同定から前臨床試験まで、開発の各段階においてオンデマンドで専門知識を活用することができ、プロジェクトのニーズや市場の需要に応じて研究開発リソースを柔軟に調整することができます。

さらに、創薬サービス・プロバイダーは、腫瘍学、免疫学、中枢神経系疾患などのニッチ分野の専門知識を提供しており、製薬企業が革新的な研究手法や知見にアクセスするのに役立っています。これらのプロバイダーは、規制ガイドラインの最新情報を常に入手し、臨床試験の要件やコンプライアンス規制を効率的に通過できるよう企業をサポートしています。専門のサービスプロバイダーにアウトソーシングすることで、企業はリスク管理を強化し、市場投入までの時間を短縮し、戦略的優先事項に集中することができます。

創薬サービス市場の成長の原動力は？

創薬サービス市場の成長の原動力は、新規治療薬に対する需要の増加、研究開発コストの上昇、生物医学研究における技術の進歩です。慢性疾患の蔓延や、がん、感染症、希少遺伝性疾患などの分野における治療需要の高まりにより、医薬品パイプラインが拡大し、より迅速でコスト効率の高い創薬プロセスが必要とされています。アウトソーシングにより、製薬会社はコストとリソースを効率的に管理しながら、この需要に対応することができます。さらに、ゲノミクス、バイオインフォマティクス、AIの進歩が研究の新たな道を開き、サービスプロバイダーはより正確で的を絞った創薬能力を提供できるようになった。

規制上の課題や複雑な臨床試験要件も、創薬サービスの採用を加速させています。サービスプロバイダーは、規制コンプライアンスを管理し、臨床開発戦略を最適化する専門知識を有しているからです。製薬会社が国際市場を開拓し、創薬の世界化が進んでいることは、サービスプロバイダーが地域の規制に関する知識やインフラをもたらすため、市場をさらに活性化させています。製薬企業の研究開発が複雑化し、コストがかかるようになる中、創薬サービス市場は、治療分野全般にわたる革新的な医薬品開発に不可欠なサポートを提供し、継続的な成長を遂げようとしています。

調査対象企業の例（注目の33社）

  • Albany Molecular Research Inc.
  • Charles River Laboratories International Inc.
  • Domainex
  • Eurofins Scientific SE
  • Evotec A.G.
  • GenScript Biotech Corporation
  • Jubilant Biosys Ltd.
  • Laboratory Corporation of America Holdings
  • Pharmaceutical Product Development LLC
  • Piramal Enterprises Ltd.
  • Selvita S.A.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP21668

Global Drug Discovery Services Market to Reach US$61.1 Billion by 2030

The global market for Drug Discovery Services estimated at US$48.6 Billion in the year 2023, is expected to reach US$61.1 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2023-2030. Medicinal Chemistry Services, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$31.6 Billion by the end of the analysis period. Growth in the Biology Services segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.9 Billion While China is Forecast to Grow at 6.9% CAGR

The Drug Discovery Services market in the U.S. is estimated at US$12.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$14.1 Billion by the year 2030 trailing a CAGR of 6.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Drug Discovery Services Market – Key Trends & Drivers Summarized

How Are Drug Discovery Services Accelerating Pharmaceutical R&D?

Drug discovery services are transforming pharmaceutical research and development (R&D) by enabling companies to outsource critical stages of drug development to specialized service providers, which enhances speed, efficiency, and cost-effectiveness. These service providers, often contract research organizations (CROs), offer expertise in areas like high-throughput screening, lead identification, preclinical research, and clinical trials, allowing pharmaceutical companies to focus on their core competencies while leveraging external capabilities. By outsourcing early-stage R&D, companies can quickly identify promising drug candidates and advance them to clinical trials, reducing the time required to bring new drugs to market and ultimately improving profitability.

In addition to expediting the drug development process, drug discovery services help pharmaceutical companies navigate the complexities of modern R&D, such as high costs, regulatory challenges, and advanced technological requirements. CROs provide access to cutting-edge technologies, including next-generation sequencing, proteomics, and bioinformatics, supporting data-intensive research and targeted drug development. This partnership model is particularly valuable for small- and medium-sized biotech firms, which may lack the resources to maintain large in-house R&D departments but still seek to drive innovation and compete in the market.

What Role Does Technology Play in Drug Discovery Services?

Technology plays a pivotal role in enhancing the capabilities and efficiency of drug discovery services, with advancements in artificial intelligence (AI), machine learning, bioinformatics, and high-throughput screening driving innovation. AI and machine learning algorithms allow CROs to analyze large datasets to identify potential drug candidates, predict compound interactions, and optimize lead compounds based on target specificity and efficacy. High-throughput screening technology enables the rapid testing of thousands of compounds against biological targets, helping to identify promising candidates early in the drug discovery process and accelerate progression through R&D stages.

In addition, computational modeling and simulation technologies aid in predicting the pharmacokinetic properties and potential toxicities of drug candidates before they enter clinical trials, reducing costly late-stage failures. Bioinformatics and molecular biology tools allow for the analysis of genetic and protein data, enabling more precise drug targeting. These technological innovations provide drug discovery service providers with advanced research capabilities, supporting pharmaceutical companies in their mission to deliver safer, more effective drugs to the market faster and with greater efficiency.

Why Are Pharmaceutical Companies Increasingly Relying on Drug Discovery Services?

Pharmaceutical companies are increasingly relying on drug discovery services to optimize R&D efficiency, access specialized expertise, and reduce costs associated with in-house development. The high fixed costs of maintaining R&D infrastructure, such as hiring specialized researchers and investing in laboratory equipment, make outsourcing a practical choice. Through drug discovery services, pharmaceutical companies can engage specialized expertise on-demand for each stage of development, from target identification to preclinical testing, providing them with the flexibility to adjust R&D resources according to project needs and market demands.

Moreover, drug discovery service providers offer expertise in niche areas like oncology, immunology, and central nervous system disorders, which helps pharmaceutical companies access innovative research methods and insights. These providers often stay updated with regulatory guidelines, supporting companies in navigating clinical trial requirements and compliance regulations efficiently. By outsourcing to specialized service providers, companies can manage risk better, accelerate time-to-market, and focus on strategic priorities, making drug discovery services an invaluable component of modern pharmaceutical R&D.

What Is Driving Growth in the Drug Discovery Services Market?

The growth in the drug discovery services market is driven by increasing demand for novel therapeutics, rising R&D costs, and technological advancements in biomedical research. The growing prevalence of chronic diseases and demand for treatments in areas such as oncology, infectious diseases, and rare genetic disorders have expanded the drug pipeline, necessitating faster and more cost-effective drug discovery processes. Outsourcing allows pharmaceutical companies to keep pace with this demand while managing costs and resources effectively. Additionally, advancements in genomics, bioinformatics, and AI have opened new avenues for research, enabling service providers to offer more precise and targeted drug discovery capabilities.

Regulatory challenges and complex clinical trial requirements have also accelerated the adoption of drug discovery services, as service providers possess the expertise to manage regulatory compliance and optimize clinical development strategies. The globalization of drug discovery, with pharmaceutical companies exploring international markets, has further fueled the market, as service providers bring regional regulatory knowledge and infrastructure. As pharmaceutical R&D becomes more complex and costly, the drug discovery services market is poised for continued growth, providing essential support for innovative drug development across therapeutic areas.

Select Competitors (Total 33 Featured) -

  • Albany Molecular Research Inc.
  • Charles River Laboratories International Inc.
  • Domainex
  • Eurofins Scientific SE
  • Evotec A.G.
  • GenScript Biotech Corporation
  • Jubilant Biosys Ltd.
  • Laboratory Corporation of America Holdings
  • Pharmaceutical Product Development LLC
  • Piramal Enterprises Ltd.
  • Selvita S.A.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Drug Discovery Services - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Focus on Innovation in Drug Discovery Drives Demand for Specialized Drug Discovery Service Providers
    • Increasing Use of AI and Machine Learning in Drug Discovery Services to Expedite Target Identification and Lead Optimization
    • Expansion of Precision Medicine and Personalized Therapies Supports Growth in Customized Drug Discovery Services
    • Rising Investment in Biologics and Small Molecule Discovery Expands Market for High-Precision Discovery Services
    • Growing Prevalence of Cancer and Autoimmune Diseases Drives Demand for Oncology-Focused Drug Discovery Services
    • Advancements in Genomics and Proteomics Fuel Demand for Target Discovery and Validation Services
    • Rising Use of High-Throughput Screening in Drug Discovery Supports Growth in Screening Services Market
    • Increased Focus on Reducing Drug Development Timelines Fuels Demand for Efficient Drug Discovery Services
    • Growing Interest in Translational Research and Biomarker Discovery Supports Demand for Early-Stage Services
    • Increased Use of Bioinformatics and Computational Modeling in Drug Discovery Services Enhances Precision in Discovery
    • Emerging Role of CRISPR and Gene Editing Technologies Expands Market for Advanced Drug Discovery Services
    • Rising Demand for Novel Drug Targets in Neurology and Psychiatry Expands Application of Drug Discovery Services
    • Increased Emphasis on Risk Mitigation in Drug Development Fuels Demand for Early Toxicology and Pharmacology Services
    • Expansion of Contract Research Organizations (CROs) Offering End-to-End Discovery Services Boosts Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Drug Discovery Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Drug Discovery Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 3: World 18-Year Perspective for Drug Discovery Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Medicinal Chemistry Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Medicinal Chemistry Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 6: World 18-Year Perspective for Medicinal Chemistry Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Biology Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Biology Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 9: World 18-Year Perspective for Biology Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Drug Metabolism & Pharmacokinetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Drug Metabolism & Pharmacokinetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 12: World 18-Year Perspective for Drug Metabolism & Pharmacokinetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 15: World 18-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 18: World 18-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 21: World 18-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 24: World 18-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Infectious & Immune System Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Infectious & Immune System Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 27: World 18-Year Perspective for Infectious & Immune System Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Digestive System Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Digestive System Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 30: World 18-Year Perspective for Digestive System Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 33: World 18-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 36: World 18-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 37: World Drug Discovery Services Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 40: USA 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 43: USA 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 46: USA 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 49: Canada 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 52: Canada 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 55: Canada 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • JAPAN
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 58: Japan 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 61: Japan 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 64: Japan 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • CHINA
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 67: China 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 70: China 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 73: China 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • EUROPE
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Drug Discovery Services by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Drug Discovery Services by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 76: Europe 18-Year Perspective for Drug Discovery Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 79: Europe 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 82: Europe 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 85: Europe 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • FRANCE
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 88: France 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 91: France 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 94: France 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • GERMANY
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 97: Germany 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 100: Germany 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 103: Germany 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 106: Italy 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 109: Italy 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 112: Italy 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • UNITED KINGDOM
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 115: UK 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 118: UK 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 121: UK 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 124: Spain 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 127: Spain 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 130: Spain 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 133: Russia 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 136: Russia 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 139: Russia 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • ASIA-PACIFIC
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Services by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Drug Discovery Services by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 18-Year Perspective for Drug Discovery Services by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • AUSTRALIA
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 163: Australia 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 166: Australia 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 169: Australia 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • INDIA
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 172: India 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 175: India 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 178: India 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 181: South Korea 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 184: South Korea 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 187: South Korea 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • LATIN AMERICA
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Drug Discovery Services by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Drug Discovery Services by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 199: Latin America 18-Year Perspective for Drug Discovery Services by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 202: Latin America 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 205: Latin America 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 208: Latin America 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 211: Argentina 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 214: Argentina 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 217: Argentina 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 220: Brazil 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 223: Brazil 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 226: Brazil 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 229: Mexico 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 232: Mexico 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 235: Mexico 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • MIDDLE EAST
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Drug Discovery Services by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Drug Discovery Services by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 247: Middle East 18-Year Perspective for Drug Discovery Services by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 250: Middle East 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 253: Middle East 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 256: Middle East 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 259: Iran 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 262: Iran 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 265: Iran 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 268: Israel 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 271: Israel 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 274: Israel 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 286: UAE 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 289: UAE 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 292: UAE 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • AFRICA
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 304: Africa 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 307: Africa 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 310: Africa 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030

IV. COMPETITION